FMT-based treatment protocol improves sleep efficiency and reduces wake after sleep onset
THURSDAY, July 23, 2026 (HealthDay News) — For adults with chronic insomnia disorder, a fecal microbiota transplantation (FMT)-based treatment protocol is associated with improved sleep continuity, according to a study published online July 22 in the Journal of Internal Medicine.
Teng Gao, from the Peking University Institute of Mental Health in Beijing, and colleagues conducted a multicenter, randomized, double-blind, placebo-controlled trial to examine whether an FMT-based treatment protocol improves sleep outcomes in adults with chronic insomnia disorder. Participants were randomly assigned to receive short-course antibiotic pretreatment followed by donor microbiota capsules or placebo capsules without antibiotic pretreatment (40 each). For prespecified exploratory subgroup analyses, participants were further randomly assigned within each group to receive synbiotic supplementation or matched placebo.
The researchers found that the FMT-based treatment protocol improved sleep efficiency (SE) compared with placebo (adjusted between-group difference, 13.9 percentage points) and reduced wake after sleep onset. There were no meaningful differences in SE in association with synbiotic assignment. From two to six months, there was sustained improvement in the Insomnia Severity Index and Pittsburgh Sleep Quality Index scores. Treatment was well tolerated; there were mild, self-limited adverse events and no serious adverse events. Microbial richness and diversity were increased, and community structure was altered with the intervention; posttreatment β-diversity change was similar in responders and nonresponders, but they had different baseline microbiota composition.
“Targeting the gut microbiota may offer a promising new therapeutic strategy for chronic insomnia disorder,” coauthor Yanping Bao, Ph.D., also from Peking University, said in a statement. “This work also strengthens our understanding of the gut-brain axis as an important regulator of human sleep.”
Abstract/Full Text (subscription or payment may be required)
Initial Rx Length Tied to Long-Term Use of Z-Drugs 
Focal Therapy Use Remains Uncommon in Nonmetastatic Prostate Cancer 
Suboptimal Adherence to Brain Health Recommendations Common in Early Alzheimer Disease 
Therapeutic Hypothermia Duration Explored in Comatose OHCA Survivors 
NEWS2 Scores Can ID Patients With Suspected Sepsis Needing Timely Treatment .jpeg)
Flu Treatment With Oseltamivir Linked to Reduced Risk for Pediatric ICU Admissions, Length of Stay 
Autonomous Oxygen Titration Increases Proportion of Time in Normoxemia 
Hypoglossal Nerve Stimulation May Offer Long-Term Cardiovascular Benefits in OSA 
